The pathophysiology of paroxysmal nocturnal hemoglobinuria

Experimental Hematology

Volumn 35, Issue 4, 2007, Pages 523-533

  Parker, Charles J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW; BONE MARROW CELL; GENE MUTATION; HEMATOPOIESIS; HUMAN; MOLECULAR CLONING; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGENY; REVIEW; SOMATIC CELL; SPINAL CORD DISEASE; STEM CELL; X CHROMOSOME LINKAGE;

ANEMIA, APLASTIC; CHROMOSOMES, HUMAN, X; HEMATOPOIESIS; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MEMBRANE PROTEINS; MOSAICISM; MUTATION; PHENOTYPE;

EID: 33947227491     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.01.046     Document Type: Review

References (93)

1. Miyata T., Takeda J., Iida Y., et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 259 (1993) 1318-1320
2. Takeda J., Miyata T., Kawagoe K., et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73 (1993) 703-711
3. Miyata T., Yamada N., Iida Y., et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 330 (1994) 249-255
4. Nicholson-Weller A., March J.P., Rosenfeld S.I., and Austen K.F. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A 80 (1983) 5066-5070
5. Pangburn M.K., Schreiber R.D., and Muller-Eberhard H.J. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A 80 (1983) 5430-5434
6. Davitz M.A., Low M.G., and Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med 163 (1986) 1150-1161
7. Holguin M.H., Fredrick L.R., Bernshaw N.J., Wilcox L.A., and Parker C.J. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 84 (1989) 7-17
8. Holguin M.H., Wilcox L.A., Bernshaw N.J., Rosse W.F., and Parker C.J. Erythrocyte membrane inhibitor of reactive lysis: effects of phosphatidylinositol-specific phospholipase C on the isolated and cell-associated protein. Blood 75 (1990) 284-289
9. Parker C.J. Hemolysis in PNH. In: Young N.S., and Moss J. (Eds). Paroxysmal Nocturnal Hemoglobinuria and the Glycosylphosphatidylinositol-Linked Proteins (2000), Academic Press, San Diego 49
10. Sloand E.M., and Young N.S. Thrombotic complications in PNH. In: Young N.S., and Moss J. (Eds). Paroxysmal Nocturnal Hemoglobinuria and the Glycosylphosphatidylinositol-Linked Proteins (2000), Academic Press, San Diego 101-112
11. Ray J.G., Burows R.F., Ginsberg J.S., and Burrows E.A. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis 30 (2000) 103-117
12. Nishimura J.I., Kanakura Y., Ware R.E., et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 83 (2004) 193-207
13. Hillmen P., Lewis S.M., Bessler M., Luzzatto L., and Dacie J.V. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 333 (1995) 1253-1258
14. Socie G., Mary J.Y., de Gramont A., et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 348 (1996) 573-577
15. Fujioka S., and Takayoshi T. Prognostic features of paroxysmal nocturnal hemoglobinuria in Japan. Acta Haematol Japan 52 (1989) 1386-1394
16. Le X.F., Yang T.Y., Yang X.Y., and Wang X.M. Characteristics of paroxysmal nocturnal hemoglobinuria in China. Clinical analysis of 476 cases. Chin Med J (Engl) 103 (1990) 885-889
17. Gongora Bianchi R.A. Paroxysmal nocturnal hemoglobinuria: the Mexican experience. Rev Invest Clin 49 (1997) 85S-88S
18. Dacie J.V., and Lewis S.M. Paroxysmal nocturnal haemoglobinuria: variation in clinical severity and association with bone-marrow hypoplasia. Br J Haematol 7 (1961) 442-457
19. Dacie J.V. Paroxsymal nocturnal haemoglobinuria. Proc R Soc Med 56 (1963) 587-596
20. Lewis S.M., and Dacie J.V. The aplastic anaemia-paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol 13 (1967) 236-251
21. Parker C.J. Historical aspects of paroxysmal nocturnal haemoglobinuria: "defining the disease.". Br J Haematol 117 (2002) 3-22
22. Rosse W.F., and Dacie J.V. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody. J Clin Invest 45 (1966) 736-748
23. Rosse W.F., and Dacie J.V. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. II. The role of complement components in the increased sensitivity of PNH red cells to immune lysis. J Clin Invest 45 (1966) 749-757
24. Rosse W.F. Variations in the red cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol 24 (1973) 327-342
25. Holguin M.H., Wilcox L.A., Bernshaw N.J., Rosse W.F., and Parker C.J. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 84 (1989) 1387-1394
26. Oni S.B., Osunkoya B.O., and Luzzatto L. Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells. Blood 36 (1970) 145-152
27. Endo M., Ware R.E., Vreeke T.M., et al. Molecular basis of the heterogeneity of expression of glycosyl phosphatidylinositol anchored proteins in paroxysmal nocturnal hemoglobinuria. Blood 87 (1996) 2546-2557
28. Mortazavi Y., Merk B., McIntosh J., Marsh J.C., Schrezenmeier H., and Rutherford T.R. The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot. Blood 101 (2003) 2833-2841
29. Bessler M., Mason P., Hillmen P., and Luzzatto L. Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria. Lancet 343 (1994) 951-953
30. Nishimura J., Inoue N., Wada H., et al. A patient with paroxysmal nocturnal hemoglobinuria bearing four independent PIG-A mutant clones. Blood 89 (1997) 3470-3476
31. Parker C., Omine M., Richards S., et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106 (2005) 3699-3709
32. Richards S.J., Cullen M.J., Dickinson A.J., Hall C., Hill A., and Hillmen P. Evolution of GPI-deficient clones predicts clinical course in paroxysmal nocturnal hemoglobinuria. Blood 104 (2004) 53a
33. Nishimura Ji J., Hirota T., Kanakura Y., et al. Long-term support of hematopoiesis by a single stem cell clone in patients with paroxysmal nocturnal hemoglobinuria. Blood 99 (2002) 2748-2751
34. Nakao S., Wang H., and Chuhjo T. Clinical significance of increased PNH-type cells in the peripheral blood of patients with aplastic anemia and refractory anemia. In: Omine M., and Kinoshita T. (Eds). Paroxysmal nocturnal hemoglobinuria and related disorders: molecular aspects of pathogenesis (2003), Springer, Tokyo 129-138
35. Ishiyama K., Chuhjo T., Wang H., Yachie A., Omine M., and Nakao S. Polyclonal hematopoiesis maintained in patients with bone marrow failure harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 102 (2003) 1211-1216
36. Wang H., Chuhjo T., Yamazaki H., et al. Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis. Eur J Haematol 66 (2001) 200-205
37. Wang H., Chuhjo T., Yasue S., Omine M., and Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 100 (2002) 3897-3902
38. Dunn D.E., Liu J.M., and Young N.S. Bone marrow failure in PNH. Paroxysmal Nocturnal Hemoglobinuria and the Glycosylphosphatidylinositol-Linked Proteins (2000), Academic Press, San Diego 113
39. Endo M., Beatty P.G., Vreeke T.M., Wittwer C.T., Singh S.P., and Parker C.J. Syngeneic bone marrow transplantation without conditioning in a patient with paroxysmal nocturnal hemoglobinuria: in vivo evidence that the mutant stem cells have a survival advantage. Blood 88 (1996) 742-750
40. Rosse W.F., Hoffman S., Campbell M., Borowitz M., Moore J.O., and Parker C.J. The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis. Br J Haematol 79 (1991) 99-107
41. Young N.S., and Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 336 (1997) 1365-1372
42. Manz C.Y., Dietrich P.Y., Schnuriger V., Nissen C., and Wodnar-Filipowicz A. T-cell receptor β chain variability in bone marrow and peripheral blood in severe acquired aplastic anemia. Blood Cells Mol Dis 23 (1997) 110-122
43. Risitano A.M., Kook H., Zeng W., Chen G., Young N.S., and Maciejewski J.P. Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by V β CDR3 spectratyping and flow cytometry. Blood 100 (2002) 178-183
44. Zeng W., Nakao S., Takamatsu H., et al. Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood 93 (1999) 3008-3016
45. Kook H., Risitano A.M., Zeng W., et al. Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood 99 (2002) 3668-3675
46. Karadimitris A., Manavalan J.S., Thaler H.T., et al. Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood 96 (2000) 2613-2620
47. Araten D.J., Nafa K., Pakdeesuwan K., and Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A 96 (1999) 5209-5214
48. Ware R.E., Pickens C.V., DeCastro C.M., and Howard T.A. Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes. Exp Hematol 29 (2001) 1403-1409
49. Hu R., Mukhina G.L., Piantadosi S., Barber J.P., Jones R.J., and Brodsky R.A. PIG-A mutations in normal hematopoiesis. Blood 105 (2005) 3848-3854
50. Kawagoe K., Kitamura D., Okabe M., et al. Glycosylphosphatidylinositol-anchor-deficient mice: implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria. Blood 87 (1996) 3600-3606
51. Rosti V., Tremml G., Soares V., Pandolfi P.P., Luzzatto L., and Bessler M. Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion. J Clin Invest 100 (1997) 1028-1036
52. Murakami Y., Kinoshita T., Maeda Y., Nakano T., Kosaka H., and Takeda J. Different roles of glycosylphosphatidylinositol in various hematopoietic cells as revealed by a mouse model of paroxysmal nocturnal hemoglobinuria. Blood 94 (1999) 2963-2970
53. Tremml G., Dominguez C., Rosti V., et al. Increased sensitivity to complement and a decreased red blood cell life span in mice mosaic for a nonfunctional Piga gene. Blood 94 (1999) 2945-2954
54. Wright B.E., Longacre A., and Reimers J.M. Hypermutation in derepressed operons of Escherichia coli K12. Proc Natl Acad Sci U S A 96 (1999) 5089-5094
55. Ball S.E., Gibson F.M., Rizzo S., Tooze J.A., Marsh J.C., and Gordon-Smith E.C. Progressive telomere shortening in aplastic anemia. Blood 91 (1998) 3582-3592
56. Brummendorf T.H., Maciejewski J.P., Mak J., Young N.S., and Lansdorp P.M. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood 97 (2001) 895-900
57. Horikawa K., Kawaguchi T., Ishihara S., et al. Frequent detection of T cells with mutations of the hypoxanthine-guanine phosphoribosyl transferase gene in patients with paroxysmal nocturnal hemoglobinuria. Blood 99 (2002) 24-29
58. Luzzatto L., and Nafa K. Genetics of PNH. In: Young N.S., and Moss J. (Eds). Paroxysmal Nocturnal Hemoglobinuria and the Glycosylphosphatidylinositol-Linked Proteins (2000), Academic Press, San Diego 21-48
59. Kinoshita T., Inoue N., and Takeda J. Defective glycosyl phosphatidylinositol anchor synthesis and paroxysmal nocturnal hemoglobinuria. Adv Immunol 60 (1995) 57-103
60. Ware R.E., Howard T.A., Kamitani T., Change H.M., Yeh E.T., and Seldin M.F. Chromosomal assignment of genes involved in glycosylphosphatidylinositol anchor biosynthesis: implications for the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood 83 (1994) 3753-3757
61. Rosse W.F., and Ware R.E. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood 86 (1995) 3277-3286
62. Murakami Y., Kosaka H., Maeda Y., et al. Inefficient response of T lymphocytes to glycosylphosphatidylinositol anchor-negative cells: implications for paroxysmal nocturnal hemoglobinuria. Blood 100 (2002) 4116-4122
63. Hertenstein B., Wagner B., Bunjes D., et al. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood 86 (1995) 1487-1492
64. Hanaoka N., Kawaguchi T., Horikawa K., et al. Decrease in sensitivity of PIG-A mutant cells to natural killer cells conferred by missing of stress-inducible membrane proteins ULBPs. Blood 104 (2004) 774a
65. Gupta P., Oegema Jr. T.R., Brazil J.J., Dudek A.Z., Slungaard A., and Verfaillie C.M. Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Blood 92 (1998) 4641-4651
66. Siebertz B., Stocker G., Drzeniek Z., Handt S., Just U., and Haubeck H.D. Expression of glypican-4 in haematopoietic-progenitor and bone-marrow-stromal cells. Biochem J 344 Pt 3 (1999 December 15) 937-943
67. Steinfeld R., Van Den Berghe H., and David G. Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican. J Cell Biol 133 (1996) 405-416
68. Jackson S.M., Nakato H., Sugiura M., et al. Dally, a Drosophila glypican, controls cellular responses to the TGF-β-related morphogen. Dpp. Development 124 (1997) 4113-4120
69. Mast A.E., Higuchi D.A., Huang Z.F., Warshawsky I., Schwartz A.L., and Broze Jr. G.J. Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem J 327 Pt 2 (1997) 577-583
70. Kim S.J., and Letterio J. Transforming growth factor-β signaling in normal and malignant hematopoiesis. Leukemia 17 (2003) 1731-1737
71. Li J., Kleeff J., Kayed H., et al. Glypican-1 antisense transfection modulates TGF-β-dependent signaling in Colo-357 pancreatic cancer cells. Biochem Biophys Res Commun 320 (2004) 1148-1155
72. Paine-Saunders S., Viviano B.L., Zupicich J., Skarnes W.C., and Saunders S. Glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol 225 (2000) 179-187
73. Tam B.Y., Finnson K.W., and Philip A. Glycosylphosphatidylinositol-anchored proteins regulate transforming growth factor-β signaling in human keratinocytes. J Biol Chem 278 (2003) 49610-49617
74. Rizzo S., Killick S.B., Patel S., et al. Reduced TGF-β1 in patients with aplastic anaemia in vivo and in vitro. Br J Haematol 107 (1999) 797-803
75. Kulkarni S., and Bessler M. Effect of proinflammatory cytokines on PIGA-hematopoiesis. Exp Hematol 31 (2003) 770-778
76. Barcellini W., Fermo E., Guia Imperiali F., et al. Increased resistance of PIG-A-bone marrow progenitors to tumor necrosis factor α and interferon γ: possible implications for the in vivo dominance of paroxysmal nocturnal hemoglobinuria clones. Haematologica 89 (2004) 651-656
77. Araten D.J., Swirsky D., Karadimitris A., et al. Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria. Br J Haematol 115 (2001) 360-368
78. Nishimura J.I., Inoue N., Azenishi Y., et al. Analysis of PIG-A gene in a patient who developed reciprocal translocation of chromosome 12 and paroxysmal nocturnal hemoglobinuria during follow-up of aplastic anemia. Am J Hematol 51 (1996) 229-233
79. Inoue N., Izui-Sarumaru T., Murakami Y., et al. Molecular basis of clonal expansion of hematopoiesis in two patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood 108 (2006) 4232-4236
80. Meyers G., Babcock W.H., Best R.G., and Parker C.J. Identification of a novel hematopoietic cell translocation in a patient with paroxysmal nocturnal hemoglobinuria. Blood 104 (2004) 15b
81. Borrmann L., Wilkening S., and Bullerdiek J. The expression of HMGA genes is regulated by their 3′ UTR. Oncogene 20 (2001) 4537-4541
82. Hess J.L., and Kossev P. Molecular genetics of benign tumors. Cancer Invest 20 (2002) 362-372
83. Grosschedl R., Giese K., and Pagel J. HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet 10 (1994) 94-100
84. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 277 (2001) 63-81
85. Tessari M.A., Gostissa M., Altamura S., et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol 23 (2003) 9104-9116
86. Santulli B., Kazmierczak B., Napolitano R., et al. A 12q13 translocation involving the HMGI-C gene in richter transformation of a chronic lymphocytic leukemia. Cancer Genet Cytogenet 119 (2000) 70-73
87. Pierantoni G.M., Santulli B., Caliendo I., et al. HMGA2 locus rearrangement in a case of acute lymphoblastic leukemia. Int J Oncol 23 (2003) 363-367
88. Andrieux J., Demory J.L., Dupriez B., et al. Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. Genes Chromosomes Cancer 39 (2004) 82-87
89. Storlazzi C.T., Albano F., Locunsolo C., et al. t(3;12)(q26;q14) in polycythemia vera is associated with upregulation of the HMGA2 gene. Leukemia 20 (2006) 2190-2192
90. Odero M.D., Grand F.H., Iqbal S., et al. Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. Leukemia 19 (2005) 245-252
91. Hillmen P., Young N.S., Schubert J., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355 (2006) 1233-1243
92. Luzzatto L., Bessler M., and Rotoli B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise?. Cell 88 (1997) 1-4
93. Frickhofen N., Heimpel H., Kaltwasser J.P., and Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 101 (2003) 1236-1242